Formation Bio raises $600m for debut fund targeting up to 15 clinical-stage drug acquisitions
Thursday, October 29, 2026 · first reported by AltAssets and 1 other
Formation Bio has announced its debut Drug Development Accelerator Fund with $600 million in capital commitments. The vehicle will finance 10 to 15 clinical-stage drug programs over three to five years, acquiring or in-licensing Phase 1 and Phase 2 assets. Limited partners include research foundations, endowments, hospitals and philanthropic organizations.
- Firm
- Formation Bio
- Fund
- Formation Bio debut fund
- Size
- $600M
- Stage
- Close
- Asset class
- Hedge funds, Private equity
- Geography
- North America
The summary and fields above are extracted from the published reports and can contain errors. The linked articles are the source of record.
See an error?
Coverage
2 sources- Quant hedge fund to spin out of Tudor in record $9bn launchFinancial Times +2
- Turkey fund crisis deepens as Takasbank CEO reportedly resignsHedgeweek
- Citadel and ExodusPoint see London macro departures amid industry shakeoutHedgeweek
- Kalshi Raised $1 Billion at a $40 Billion Valuation in a Round Co-Led by Sequoia and WellingtonHedgeCo
- Hedge fund Arini sells $800 million in debt as losses mount - WSJinvesting.com
- Treasury announces first Outbound Investment Security Program penalty for failure to notifyMcDermott Will & Schulte via JD Supra +1
Got news? Send it to us →